07.02.2017 • News

Solvay Takes DuPont’s Energain Li-Ion Technology

(c) Solvay
(c) Solvay

Belgian chemical group Solvay has acquired DuPont’s Energain lithium-ion high voltage technology for an undisclosed sum. The Brussels-headquartered company said Energain will expand its Special Chem Global Business Unit’s existing portfolio of high-performance salts and additives for electrolytes and strengthen its development capabilities for Li-ion batteries.

Nicolas Cudré-Mauroux, Solvay’s general manager of research & innovation added that the acquisition reinforced the group’s competencies in areas such as modelling and formulations.

The advanced Li-ion battery market is developing rapidly, noted Solvay, driven by increasingly stringent regulations and continuous improvements in performance and cost.

According to a September 2016 report by US-based Transparency Market Research (TMR), a growing shift toward sustainable clean fuels in the automotive sector is a key factor driving the Li-ion battery market. TMR said rising demand for high-power capacity batteries in cars as well as increasing sales of smartphones and other consumer electronics are fuelling growth worldwide. It projects the value of the global Li-ion market to rise from nearly $30 billion in 2015 to more than $77 billion in 2024, showing a compound annual growth rate of 11.6%.

 

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read